Cargando…
BSCI-17. Targeting SIRPα as a therapeutic strategy for the treatment of breast cancer brain metastasis
Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer characterized by the lack of druggable targets and an incidence of brain metastasis from the primary site of approximately 35%. There is no standard treatment for managing brain metastasis associated with TNBC; ther...
Autores principales: | Stirling, Elizabeth R, Bronson, Steven M, Crowe, William N, Wilson, Adam, Kooshki, Mitra, Zhao, Dawen, Triozzi, Pierre L, Lesser, Glenn J, Soto-Pantoja, David R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351265/ http://dx.doi.org/10.1093/noajnl/vdab071.016 |
Ejemplares similares
-
BSCI-19. Therapeutic intervention of lung-, breast-, and melanoma-brain metastasis
por: Kieliszek, Agata, et al.
Publicado: (2021) -
BSCI-01. Small RNAseq analysis of microRNAs in brain metastasis
por: Jancalek, Radim, et al.
Publicado: (2021) -
BSCI-12. Inhibition of melanoma brain metastasis by targeting miR-146a
por: Wang, Jiwei, et al.
Publicado: (2021) -
BSCI-16. Olfactory receptor 5B21 drives breast cancer metastasis
por: Li, Mao, et al.
Publicado: (2021) -
BSCI-02. METPlatform identifies brain metastasis vulnerabilities and predicts patient response to therapy
por: Zhu, Lucía, et al.
Publicado: (2021)